ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

eltrombopag

Also written as “Eltrombopag”, “SB497115” and “Eltrombopag olamine”.

Its studies are mostly in Purpura, Thrombocytopenic, Idiopathic · Thrombocytopenia · Anemia, Aplastic · Purpura · Hepatitis C, Chronic, led by 4 companies.

Drug pageEltrombopag: every studyAll 135 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jan 7, 201049 company-led studies, 3 open or runningNext primary completion: Apr 22, 2033 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKlineits history only290 open or runningphase 4since Jan 7, 2010Feb 1, 2005none ahead
Novartis182 open or runningphase 4since Oct 4, 2013Jul 10, 2006Apr 22, 2033phase 2 · NCT07660172
Bristol-Myers Squibbits history only10 open or runningphase 1since Jun 20, 2023Jun 20, 2023none ahead
Renataits history only11 open or runningphase 2since Jul 6, 2024Jul 6, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novartis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 4 studies since Jul 10, 2006.

  1. Jun 27, 2013Phase 2 study in LeukemiaNCT01890746 · 148 enrolled · United States, Australia, Belgium and more
  2. Oct 4, 2013Phase 4 study in ThrombocytopeniaNCT01957176 · 22 enrolled · Belgium, China, France and more
  3. May 22, 2014Phase 2 study in Anemia, AplasticNCT02148133 · 21 enrolled · Japan
  4. Jun 5, 2014Phase 3 study in ThrombocytopeniaNCT02158936 · 356 enrolled · United States, Argentina, Australia and more
  5. Feb 26, 2015Phase 2 study in Anemia, AplasticNCT02404025 · 10 enrolled · Japan
  6. Nov 4, 2016Phase 2 study in Anemia, AplasticNCT02998645 · 54 enrolled · Brazil, Hong Kong, India and more
  7. Jan 12, 2017Phase 2 study in Anemia, AplasticNCT03025698 · 51 enrolled · United States, Hong Kong, Portugal and more
  8. May 2, 2018Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT03524612 · 105 enrolled · United States, Austria, Brazil and more
  9. Oct 23, 2018Phase 2 study in Poor Graft FunctionNCT03718533 · 10 enrolled · Spain
  10. Jun 13, 2019Phase 2 study in Anemia, AplasticNCT03988608 · 20 enrolled · China
  11. Mar 9, 2020Phase 2 study in Anemia, AplasticNCT04328727 · 36 enrolled · China, Japan, South Korea and more
  12. Apr 12, 2020Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT04346654 · 26 enrolled · Germany
  13. Mar 4, 2021Phase 2 study in Myelodysplastic SyndromesNCT04797000 · 36 enrolled · Japan
  14. Jun 15, 2026Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT07660172 · 36 planned

Ahead

  1. Apr 22, 2033Primary completion: phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT07660172

TargetBeta

MPL →read by rule
“Thrombopoietin receptor agonist; Thrombopoietin receptor agonist”ChEMBL 37, by rule

Other programs on MPL

ProgramCompanyFurthest phaseStudies
romiplostimruleAmgenphase 438
avatrombopagruleEisaiphase 425
hetrombopag olamineruleJiangsu HengRui Medicinephase 315

Studies

All 18 Novartis leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07660172Purpura, Thrombocytopenic, Idiopathic2Not yet recruitingApr 22, 203336
NCT04797000Myelodysplastic Syndromes · Japan2Active, not recruitingApr 26, 202536
NCT04346654Purpura, Thrombocytopenic, Idiopathic · Germany2CompletedSep 22, 202326
NCT04328727Anemia, Aplastic · China, Japan, South Korea and more2CompletedJun 10, 202236
NCT03988608Anemia, Aplastic · China2CompletedJul 16, 202120
NCT03718533Poor Graft Function · Spain2TerminatedNov 3, 202010
NCT03524612Purpura, Thrombocytopenic, Idiopathic · United States, Austria, Brazil and more2CompletedOct 22, 2021105
NCT03025698Anemia, Aplastic · United States, Hong Kong, Portugal and more2CompletedApr 22, 202251
NCT02998645Anemia, Aplastic · Brazil, Hong Kong, India and more2CompletedNov 3, 202054
NCT02404025Anemia, Aplastic · Japan2CompletedJul 5, 201610
NCT02158936Thrombocytopenia · United States, Argentina, Australia and more3TerminatedApr 30, 2016356
NCT02148133Anemia, Aplastic · Japan2CompletedSep 10, 201521
NCT01957176Thrombocytopenia · Belgium, China, France and more4CompletedFeb 23, 202222
NCT01890746Leukemia · United States, Australia, Belgium and more2CompletedMar 13, 2015148
NCT02201290Purpura, Thrombocytopenic, Idiopathic · Russian Federation3CompletedJul 4, 20179
NCT01762761Purpura · China3CompletedJun 5, 2014155
NCT01440374Thrombocytopenia · United States, Argentina, Belgium and more2CompletedMar 2015162
NCT00351468Purpura · United States, Australia, Austria and more3CompletedJul 2015302

How it is read

Names in the registry

  • “Eltrombopag”, 19 entries
  • “eltrombopag”, 15 entries
  • “SB497115”, 3 entries
  • “Eltrombopag olamine”, 2 entries
  • “Eltrombopag 25 MG”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.